Venus Medtech Acquires InterValve


June 14, 2017—Venus Medtech Inc. announced that it has purchased InterValve, Inc. Beginning in June 2017, Venus Medtech will be responsible for the global production and sales of InterValve's V8 and TAV8 aortic valvuloplasty balloon catheters used in transcatheter aortic valve replacement (TAVR). The V8 and TAV8 have received US Food and Drug Administration and European CE Mark approvals. Venus Medtech is based in Hangzhou, China. InterValve is based in Plymouth, Minnesota.

In April, Venus Medtech announced that its Venus A-valve TAVR system has been approved by the China Food and Drug Administration (CFDA) for sale in China for the treatment of inoperable and high-risk patients. This is China's first homemade TAVR device and the first CFDA-approved TAVR device. In addition to the launch in the Chinese market, Venus Medtech has started its global expansion of the Venus A-valve.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.